The British Journal of Psychiatry 136: 1-25 (1980)
© 1980 The Royal College of Psychiatrists

Clomipramine and exposure for obsessive-compulsive rituals: i

IM Marks, RS Stern, D Mawson, J Cobb and R McDonald

Forty chronic obsessive-compulsive ritualizers were randomly assigned to treatment with oral clomipramine or placebo for 8 months. During weeks 4 to 7 these two groups were each randomly split into treatment by relaxation or by exposure in vivo, and during weeks 7 to 10 all patients had exposure in vivo. Double blind assessments were made at weeks 4, 7, 10, 18, 36, 62 and 114. Results are reported to one year. Clomipramine produced significant improvement in rituals, mood and social adjustment, but only in those patients who initially had depressed mood. The clomipramine effect was maximum from weeks 10 to 18 and diminished thereafter. On stopping clomipramine patients often relapsed and improved again on restarting the drug. Relaxation produced little change. Exposure produced significant lasting improvement in rituals, but less change in mood; improvement generalized to social adjustment at follow-up. Clomipramine plus exposure had a slight additive but not interactional effect. Clomipramine enhanced compliance both with exposure and with relaxation. Clomipramine is useful for compulsive ritualizers with depressed mood, but may need continuation for over a year and combination with exposure in vivo. Exposure in vivo remains the treatment of choice for rituals without depressed mood.

This article has been cited by other articles:

				E. B. Foa, M. R. Liebowitz, M. J. Kozak, S. Davies, R. Campeas, M. E. Franklin, J. D. Huppert, K. Kjernisted, V. Rowan, A. B. Schmidt, et al. Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder Focus, January 1, 2007; 5(3): 368 - 380. [Abstract] [Full Text] [PDF]

				G. Chouinard The Search for New Off-Label Indications for Antidepressant, Antianxiety, Antipsychotic and Anticonvulsant Drugs Focus, September 1, 2006; 4(4): 528. [Full Text] [PDF]

				E. B. Foa, M. R. Liebowitz, M. J. Kozak, S. Davies, R. Campeas, M. E. Franklin, J. D. Huppert, K. Kjernisted, V. Rowan, A. B. Schmidt, et al. Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder Am J Psychiatry, January 1, 2005; 162(1): 151 - 161. [Abstract] [Full Text] [PDF]

				B. L. Van Noppen and G. Steketee Individual, Group, and Multifamily Cognitive-Behavioral Treatments Focus, July 1, 2004; 2(3): 475 - 495. [Full Text] [PDF]

				S. Saxena, A. L. Brody, M. L. Ho, S. Alborzian, K. M. Maidment, N. Zohrabi, M. K. Ho, S.-C. Huang, H.-M. Wu, and L. R. Baxter Jr Differential Cerebral Metabolic Changes With Paroxetine Treatment of Obsessive-Compulsive Disorder vs Major Depression Arch Gen Psychiatry, March 1, 2002; 59(3): 250 - 261. [Abstract] [Full Text] [PDF]

				D. F. Klein Flawed Meta-Analyses Comparing Psychotherapy With Pharmacotherapy Am J Psychiatry, August 1, 2000; 157(8): 1204 - 1211. [Abstract] [Full Text]

				I. Marks, K. Lovell, H. Noshirvani, M. Livanou, and S. Thrasher Treatment of Posttraumatic Stress Disorder by Exposure and/or Cognitive Restructuring: A Controlled Study Arch Gen Psychiatry, April 1, 1998; 55(4): 317 - 325. [Abstract] [Full Text] [PDF]

				R. Cladouceur, M. H. Freeston, F. Gagnon, N. Cthibodeau, and J. Dumont Cognitive-Behavioral Treatment of Obsessions Behav Modif, April 1, 1995; 19(2): 247 - 257. [Abstract]

				J.V. Lucey BAP/SKB Young Psychopharmacologist Award Towards a neuroendocrinology of obsessive-compulsive disorder J Psychopharmacol, January 1, 1994; 8(4): 250 - 257. [Abstract] [PDF]

				D. T. Healy The psychopharmacological era: notes toward a history J Psychopharmacol, January 1, 1990; 4(3): 152 - 167. [Abstract] [PDF]